Hypoxia-induced pulmonary hypertension: Different impact of iloprost, sildenafil, and nitric oxide

Respiratory Medicine

Volumn 101, Issue 10, 2007, Pages 2125-2132

  Weissmann, Norbert ^a   Gerigk, Boris ^a   Kocer, Özlem ^a   Nollen, Matthias ^a   Hackemack, Sascha ^a   Ghofrani, Hossein Ardeschir ^a   Schermuly, Ralph Theo ^a   Butrous, Ghazwan ^b   Schulz, Andreas ^c   Roth, Markus ^a   Seeger, Werner ^a   Grimminger, Friedrich ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^c BAYER PHARMA AG   (Germany)

Author keywords

Iloprost; NO; Pulmonary hypertension; Right heart failure; Sildenafil

Indexed keywords

ILOPROST; NITRIC OXIDE; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HYPOXIA; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; RABBIT; VASCULAR SMOOTH MUSCLE;

ANALYSIS OF VARIANCE; ANIMALS; ANOXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HYPERTENSION, PULMONARY; ILOPROST; NITRIC OXIDE; PIPERAZINES; PURINES; RABBITS; SULFONES; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 34548274991     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.05.025     Document Type: Article

References (31)

1. Durmowicz A.G., and Stenmark K.R. Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 20 11 (1999) e91-e102
2. Shimoda L.A., Sham J.S., and Sylvester J.T. Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol Res 49 5 (2000) 549-560
3. Jeffery T.K., and Wanstall J.C. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92 1 (2001) 1-20
4. Weissmann N., Nollen M., Gerigk B., Ardeschir G.H., Schermuly R.T., Gunther A., et al. Downregulation of hypoxic vasoconstriction by chronic hypoxia in rabbits: effects of nitric oxide. Am J Physiol Heart Circ Physiol 284 3 (2003) H931-H938
5. Geraci M.W., Gao B., Shepherd D.C., Moore M.D., Westcott J.Y., Fagan K.A., et al. Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest 103 11 (1999) 1509-1515
6. Kouyoumdjian C., Adnot S., Levame M., Eddahibi S., Bousbaa H., and Raffestin B. Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J Clin Invest 94 2 (1994) 578-584
7. Horstman D.J., Frank D.U., and Rich G.F. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats. Anesth Analg 86 1 (1998) 74-81
8. Zhao L., Mason N.A., Morrell N.W., Kojonazarov B., Sadykov A., Maripov A., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104 4 (2001) 424-428
9. Zhao L., Mason N.A., Strange J.W., Walker H., and Wilkins M.R. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity. Circulation 107 2 (2003) 234-237
10. Phillips P.G., Long L., Wilkins M.R., and Morrell N.W. Cyclic AMP phosphodiesterase inhibitors potentiate effects of prostacyclin analogues in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 288 1 (2005) L103-L115
11. Sebkhi A., Strange J.W., Phillips S.C., Wharton J., and Wilkins M.R. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107 25 (2003) 3230-3235
12. Griffiths M.J., and Evans T.W. Inhaled nitric oxide therapy in adults. N Engl J Med 353 25 (2005) 2683-2695
13. Hermle G., Schutte H., Walmrath D., Geiger K., Seeger W., and Grimminger F. Ventilation-perfusion mismatch after lung ischemia-reperfusion. Protective effect of nitric oxide. Am J Respir Crit Care Med 160 4 (1999) 1179-1187
14. Walmrath D., Schermuly R., Pilch J., Grimminger F., and Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 10 5 (1997) 1084-1092
15. Schermuly R.T., Inholte C., Ghofrani H.A., Gall H., Weissmann N., Weidenbach A., et al. Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. Respir Res 6 (2005) 76
16. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Samidurai A., Pullamsetti S., Weissmann N., et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94 8 (2004) 1101-1108
17. Weissmann N., Grimminger F., Walmrath D., and Seeger W. Hypoxic vasoconstriction in buffer-perfused rabbit lungs. Respir Physiol 100 2 (1995) 159-169
18. Weissmann N., Grimminger F., Voswinckel R., Conzen J., and Seeger W. Nitro blue tetrazolium inhibits but does not mimic hypoxic vasoconstriction in isolated rabbit lungs. Am J Physiol 274 5 Pt 1 (1998) L721-L727
19. Weissmann N., Voswinckel R., Hardebusch T., Rosseau S., Ghofrani H.A., Schermuly R., et al. Evidence for a role of protein kinase C in hypoxic pulmonary vasoconstriction. Am J Physiol 276 1 Pt 1 (1999) L90-L95
20. Weissmann N., Tadic A., Hanze J., Rose F., Winterhalder S., Nollen M., et al. Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)?. Am J Physiol Lung Cell Mol Physiol 279 4 (2000) L683-L690
21. Spriestersbach R., Grimminger F., Weissmann N., Walmrath D., and Seeger W. On-line measurement of nitric oxide generation in buffer-perfused rabbit lungs. J Appl Physiol 78 4 (1995) 1502-1508
22. Ozaki M., Kawashima S., Yamashita T., Ohashi Y., Rikitake Y., Inoue N., et al. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 37 2 (2001) 322-327
23. Grimminger F., Spriestersbach R., Weissmann N., Walmrath D., and Seeger W. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 78 4 (1995) 1509-1515
24. Sauzeau V., Rolli-Derkinderen M., Lehoux S., Loirand G., and Pacaud P. Sildenafil prevents change in RhoA expression induced by chronic hypoxia in rat pulmonary artery. Circ Res 93 7 (2003) 630-637
25. Faber M.J., Dalinghaus M., Lankhuizen I.M., Bezstarosti K., Dekkers D.H., Duncker D.J., et al. Proteomic changes in the pressure overloaded right ventricle after 6 weeks in young rats: correlations with the degree of hypertrophy. Proteomics 5 10 (2005) 2519-2530
26. Adachi S., Ito H., Ohta Y., Tanaka M., Ishiyama S., Nagata M., et al. Distribution of mRNAs for natriuretic peptides in RV hypertrophy after pulmonary arterial banding. Am J Physiol 268 1 Pt 2 (1995) H162-H169
27. Takimoto E., Champion H.C., Li M., Belardi D., Ren S., Rodriguez E.R., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 2 (2005) 214-222
28. Hyvelin J.M., Howell K., Nichol A., Costello C.M., Preston R.J., and McLoughlin P. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97 2 (2005) 185-191
29. Frank D.U., Horstman D.J., and Rich G.F. The effect of prolonged inhaled nitric oxide on pulmonary vasoconstriction in rats. Anesth Analg 87 6 (1998) 1285-1290
30. Higenbottam T.W., Butt A.Y., Nh-Xaun A.T., Takao M., Cremona G., and Akamine S. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart 79 2 (1998) 175-179
31. Schermuly R.T., Yilmaz H., Ghofrani H.A., Woyda K., Pullamsetti S., Schulz A., et al. Inhaled iloprost reverses vascular remodeling in chronic experimental pulmonary hypertension. Am J Respir Crit Care Med 172 3 (2005) 358-363